Overview

Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor

Status:
Completed

Trial end date:
2015-06-01

Target enrollment:

Participant gender:

Summary

Patients with neovascular age-related macular degeneration who do not respond to usual treatment with conventional medications may respond to a new drug of the same class which is designed to block a larger fraction of proangiogenic factors.

Phase:

Phase 4

Details

Lead Sponsor:

Barcelona Macula Foundation

Collaborators:

Bayer
TFS Trial Form Support

Treatments:

Aflibercept
Endothelial Growth Factors
Mitogens